PriceTargets.com logo

Cara Therapeutics - CARA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.00
  • Forecasted Upside: 245.53%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$4.92 As of 03/24/2023 01:00 AM ET
▼ -0.14 (-2.77%)

This chart shows the closing price for CARA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cara Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CARA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CARA

Analyst Price Target is $17.00
▲ +245.53% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Cara Therapeutics in the last 3 months. The average price target is $17.00, with a high forecast of $25.00 and a low forecast of $6.00. The average price target represents a 245.53% upside from the last price of $4.92.

This chart shows the closing price for CARA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Cara Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2023Canaccord Genuity GroupLower TargetBuy$29.00 ➝ $25.00Low
3/7/2023JPMorgan Chase & Co.Lower TargetOverweight$19.00 ➝ $16.00Low
3/7/2023Bank of AmericaDowngradeNeutral ➝ Underperform$13.00 ➝ $6.00Low
3/7/2023Needham & Company LLCLower TargetBuy$26.00 ➝ $22.00Low
3/7/2023HC WainwrightLower TargetBuy$25.00 ➝ $20.00Low
3/7/2023Piper SandlerLower TargetOverweight$25.00 ➝ $13.00Low
2/17/2023Needham & Company LLCReiterated RatingBuy$26.00N/A
2/14/2023HC WainwrightLower TargetBuy$30.00 ➝ $25.00Low
11/15/2022Piper SandlerLower Target$25.00N/A
3/14/2022Canaccord Genuity GroupLower Target$33.00 ➝ $29.00High
3/14/2022HC WainwrightLower TargetBuy$35.00 ➝ $30.00Low
3/14/2022Canaccord Genuity GroupLower TargetBuy$33.00 ➝ $29.00Low
3/8/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$17.00 ➝ $20.00High
8/24/2021Needham & Company LLCInitiated CoverageBuy$26.00High
8/24/2021HC WainwrightBoost TargetBuy$33.00 ➝ $35.00High
8/10/2021Needham & Company LLCInitiated CoverageBuy$26.00High
8/3/2021JPMorgan Chase & Co.Initiated CoverageNeutral$16.00High
4/29/2021Needham & Company LLCLower TargetBuy$35.00 ➝ $26.00High
4/15/2021Needham & Company LLCReiterated RatingBuy$35.00Low
8/11/2020Needham & Company LLCReiterated RatingBuy$35.00Low
6/18/2020Needham & Company LLCReiterated RatingBuy$35.00Medium
5/19/2020Cantor FitzgeraldBoost TargetOverweight$34.00 ➝ $40.00Low
4/22/2020Cantor FitzgeraldBoost TargetOverweight$26.00 ➝ $34.00Medium
4/21/2020Needham & Company LLCInitiated CoverageBuy$35.00Low
4/21/2020HC WainwrightBoost TargetPositive ➝ Buy$30.00 ➝ $33.00High
12/4/2019Cantor FitzgeraldBoost Target$29.00 ➝ $33.00High
12/3/2019Needham & Company LLCReiterated RatingBuy$35.00High
12/3/2019HC WainwrightReiterated RatingBuy$30.00High
10/17/2019Needham & Company LLCReiterated RatingBuy$35.00Low
8/12/2019HC WainwrightReiterated RatingBuy ➝ Buy$31.00 ➝ $30.00Low
7/30/2019Piper Jaffray CompaniesBoost TargetOverweight$35.00 ➝ $39.00Medium
7/22/2019HC WainwrightBoost TargetBuy ➝ Average$28.00 ➝ $31.00Low
5/29/2019LaidlawBoost TargetBuy$26.00 ➝ $32.00Low
5/29/2019HC WainwrightBoost TargetBuy$26.00 ➝ $28.00High
5/29/2019Needham & Company LLCBoost TargetBuy$28.00 ➝ $35.00High
2/6/2019Jefferies Financial GroupInitiated CoverageBuy$22.00Low
1/15/2019Bank of AmericaInitiated CoverageNeutral$19.00Low
12/20/2018HC WainwrightSet TargetBuy$30.00Low
12/20/2018LaidlawSet TargetBuy$30.00Low
12/20/2018Piper Jaffray CompaniesSet TargetBuy$27.00Low
12/20/2018Janney Montgomery ScottInitiated CoverageBuy$27.00 ➝ $13.36High
11/7/2018Cantor FitzgeraldSet TargetBuy$27.00High
10/4/2018Cantor FitzgeraldReiterated RatingBuy$27.00High
9/21/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$27.00High
9/13/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$30.00High
8/8/2018Stifel NicolausBoost TargetBuy ➝ Buy$22.00 ➝ $26.00High
8/8/2018HC WainwrightSet TargetBuy$26.00High
6/28/2018HC WainwrightBoost TargetPositive ➝ Buy$24.00 ➝ $26.00High
6/27/2018Needham & Company LLCBoost TargetPositive ➝ Buy$23.00 ➝ $28.00High
5/24/2018LaidlawSet TargetBuy$26.00Low
5/23/2018HC WainwrightBoost TargetBuy ➝ Buy$22.00 ➝ $24.00High
5/23/2018Stifel NicolausBoost TargetBuy$20.00High
5/11/2018HC WainwrightSet TargetBuy$22.00Low
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
9/27/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/25/2023
  • 5 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/24/2023
  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Cara Therapeutics logo
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Read More

Today's Range

Now: $4.92
Low: $4.85
High: $5.09

50 Day Range

MA: $9.56
Low: $4.92
High: $12.27

52 Week Range

Now: $4.92
Low: $4.85
High: $13.97

Volume

495,138 shs

Average Volume

1,026,606 shs

Market Capitalization

$265.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Cara Therapeutics?

The following Wall Street research analysts have issued stock ratings on Cara Therapeutics in the last year: Bank of America Co., Canaccord Genuity Group Inc., HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, and StockNews.com.
View the latest analyst ratings for CARA.

What is the current price target for Cara Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Cara Therapeutics in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 245.5%. Canaccord Genuity Group Inc. has the highest price target set, predicting CARA will reach $25.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $6.00 for Cara Therapeutics in the next year.
View the latest price targets for CARA.

What is the current consensus analyst rating for Cara Therapeutics?

Cara Therapeutics currently has 1 sell rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CARA will outperform the market and that investors should add to their positions of Cara Therapeutics.
View the latest ratings for CARA.

What other companies compete with Cara Therapeutics?

Other companies that are similar to Cara Therapeutics include I-Mab, Atea Pharmaceuticals, Precigen, Vaxxinity and Immuneering. Learn More about companies similar to Cara Therapeutics.

How do I contact Cara Therapeutics' investor relations team?

Cara Therapeutics' physical mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company's listed phone number is (203) 406-3700 and its investor relations email address is [email protected] The official website for Cara Therapeutics is www.caratherapeutics.com. Learn More about contacing Cara Therapeutics investor relations.